David explored Real World Data on outcomes of successive regimens involving anti-PDx-1 in advanced and metastatic non-small cell lung cancer. He found different oncology treatment regimens delivered in different sequences resulted in better or worse outcomes depending on the sequence.

“The patient matching technology Inteliquet deploys to facilitate clinical trial feasibility and patient recruitment holds immense potential not just for trial design and implementation, but also new critical insights for medicine,” said Inteliquet President and COO Marie E Lamont. “This is another example of the power of the Inteliquet Cancer Center Research Consortium and value of well-organized and intelligently used data.”

Read the release here